Updated:
Yonjin Venture
Yonjin Venture is the North America and Europe investment arm of Yongjin Group, based in Shanghai with headquarters in China. It focuses on early- and...
Yonjin Venture
Yonjin Venture is the North America and Europe investment arm of Yongjin Group, based in Shanghai with headquarters in China. It focuses on early- and mid-stage life science companies in therapeutics, diagnostics, and medical devices. Yonjin Venture has made 18 investments, including a Series A - V investment in Rapafusyn Pharmaceuticals on September 04, 2025.
General information
Firm type
Venture Capital
Location
Region
North America
Country
United States
City
Cambridge
Corporate office
Cambridge, MA, United States
Frequently asked questions
Who runs investment decisions at Yonjin Venture?
No named principals or investment committee members appear in public records, regulatory filings, or press coverage. The firm does not maintain a public LinkedIn page or list team members on its website. This absence of disclosed leadership makes it difficult for external allocators to assess the decision-making structure or track record of the individuals deploying capital.
How can an institutional allocator conduct due diligence on Yonjin Venture?
Allocators face significant hurdles given the absence of public portfolio data, team biographies, fund performance, or regulatory filings. Direct outreach to the firm via its website remains the only visible path to initiate diligence. Without audited financials, track record documentation, or referenceable co-investors, the firm falls below standard institutional due-diligence thresholds as of the current public record.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: